CRL Stock Forecast & Price Target

Charles River is supported by a resilient outsourced preclinical model that has delivered 16% annualized earnings growth over the past 10 years, with demand improving in DSA as biotech funding stabilizes and large pharma reprioritizes pipeline work toward IND-enabling studies. Its 5%-7% organic revenue growth and double-digit EPS growth outlook through 2030 are backed by margin expansion from divestitures, pricing normalization, automation, and more than $300M of planned savings, while management sees BioAnalysis as a meaningful incremental growth lever. The post-CDMO portfolio also looks higher quality, with Manufacturing targeting 7%-9% organic growth and >40% operating margins, and the broader business benefits from 220+ NAM capabilities, recurring microbial consumables, and a stronger position across the drug development lifecycle.

Charles River is facing a negative fundamental outlook because demand for preclinical and IND-enabling services remains vulnerable to biotech funding constraints, pipeline cuts, tighter capital markets, and a shift toward in-house development by customers. Its earnings recovery also depends on successful vertical integration and margin expansion, yet integration challenges, NHP cost inflation, lower utilization, or geopolitical disruptions could prevent the anticipated 120 bps margin uplift and the guided $16M in 2026 and $39M in 2027 EPS accretion. In addition, the company’s exposure to NHP-related revenue decline in 2027 and 2028 and limited NAMs capabilities around $120M raise the risk of structural revenue erosion in a core high-margin segment.